These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Not reported Terminated 2004-005001-29 Efficacy and safety of ozarelix acetate, a new GnRH antagonist in male patients with mild to moderate Alzheimer’s Disease (Regimen: 130 mg q4w, x3) 2007-12-17 due-trials
Listed as ongoing, but also has a completion date 2007-002598-30 Cetrorelix pamoate (AEZS-102) in patients with symptomatic BPH: a double-blind placebo-controlled efficacy study 2009-12-16 bad-data
Completed, but no date 2007-002663-26 Antitumoral activity and safety of AEZS-108 (AN-152), a LHRH agonist linked doxorubicin, in women with LHRH receptor positive gynecological tumors bad-data
Not reported Terminated 2007-003414-34 Cetrorelix pamoate intermittent IM dosage regimens in patients with symptomatic BPH: a 1year placebo-controlled efficacy study and long-term safety assessment 2009-12-16 due-trials
Completed, but no date Terminated 2007-004865-17 Cetrorelix pamoate (AEZS-102) in patients with symptomatic BPH: an open-labeled safety and efficacy assessment study bad-data
Not reported Terminated 2010-018893-19 A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients Previously Treated with Bortezomib 2013-03-11 due-trials
Not reported 2012-000134-19 A randomised, phase 2 trial of AEZS-108 in chemotherapy refractory triple negative (ER/PR/HER2-negative) LHRH-R positive metastatic breast cancer 2014-06-10 due-trials
Reported results 2012-005546-38 Randomised controlled study comparing AEZS-108 with doxorubicin as second line therapy for locally advanced, recurrent or metastatic endometrial cancer 2017-03-02 due-trials
Reported results 2015-002337-22 Confirmatory validation of oral macimorelin as a Growth Hormone (GH) Stimulation Test (ST) for the diagnosis of Adult Growth Hormone Deficiency (AGHD) in comparison with the Insulin Tolerance Test (IT... 2016-12-29 due-trials
Completed, reported early 2018-001988-23 Open label, group comparison, dose escalation trial to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of macimorelin acetate after single oral dosing of 0.25 mg/kg, 0.5 mg/kg,... 2020-01-24 not-yet-due